Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
09/2005
09/22/2005CA2563739A1 Bioavailable solid dosage forms of metaxalone
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576964A1 Protease inhibitor
09/21/2005EP1575964A2 N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
09/21/2005EP1575528A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
09/21/2005EP1575524A2 Proliferated cell lines and uses thereof
09/21/2005EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
09/21/2005EP1411961B1 Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
09/21/2005EP1303501B1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
09/21/2005EP1265862B1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
09/21/2005EP1061805B1 Regulation of endogenous gene expression in cells using zinc finger proteins
09/21/2005CN1671837A Neutralizing human anti-IGFR antibody
09/21/2005CN1671742A Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair
09/21/2005CN1671715A Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
09/21/2005CN1671701A Novel aryllimidazole derivatives, preparation and therapeutic used thereof
09/21/2005CN1671696A 激酶抑制剂 Kinase inhibitors
09/21/2005CN1671671A 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) im
09/21/2005CN1671387A Aryl substituted hydantoin compounds and their use as sodium channel blockers
09/21/2005CN1219780C Heterocyclic compounds binding chemotactic factor receptor
09/21/2005CN1219748C Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride
09/21/2005CN1219556C The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
09/20/2005US6946474 Nitrogen-containing compounds and their use as glycine transport inhibitors
09/20/2005US6946129 Recombinant anti-CD40 antibody and uses thereof
09/20/2005US6945247 Method of treating cardio pulmonary diseases with no group compounds
09/15/2005WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient
09/15/2005US20050203125 Treating pseudobulbar affect or emotional lability; nervous system, brain, and neurodegenerative disorders; analgesics; neuropathic pain; dextromethorphan hydrobromide and quinidine sulfate
09/15/2005US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular
09/15/2005US20050203109 Novel Compounds
09/15/2005US20050203066 Preventing mitochondrial respiratory chain dysfunction in mammal by administering a pyrimidine nucleotide precursor and pyruvic acid, ester or salt; neurodegenerative, muscular, urogenital, or developmental disorders; autism, neuropathic pain, headaches; anticarcinogenic agents; cognition activators
09/15/2005US20050202107 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass
09/15/2005US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
09/15/2005CA2558478A1 Alk7 and myostatin inhibitors and uses thereof
09/14/2005EP1574578A1 Monomeric protein of the TGF-beta family
09/14/2005EP1574207A1 Cosmetic use of viscous compositions containing carbon dioxide
09/14/2005EP1573003A2 Method for producing transgenic animals using oral gene therapy
09/14/2005EP1572988A1 Culture medium composition, culture method, and myoblasts obtained, and their uses
09/14/2005EP1572934A2 Follistatin domain containing proteins
09/14/2005EP1572909A2 A follistatin domain containing protein
09/14/2005EP1572881A2 Tacis and br3 polypeptides and uses thereof
09/14/2005EP1572877A2 Drug metabolizing enzymes
09/14/2005EP1572243A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent
09/14/2005EP1572071A2 Systems and methods for treating patients with processed lipoaspirate cells
09/14/2005EP1572065A2 Method and pharmaceutical composition for the treatment of multiple sclerosis
09/14/2005EP1392643B1 Trisubstituted-n- (1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
09/14/2005EP1284958B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives
09/14/2005EP0981343B1 Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
09/14/2005CN1668621A Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands
09/14/2005CN1668619A Imidazo[1, 2-a]pyrazin-8-ylamines, method of making and method of use thereof
09/14/2005CN1668588A Indole derivatives, method for preparing same and pharmaceutical compositions containing same
09/14/2005CN1668586A Method for preparing 13 5-triaminobenzene and hydrolyzing it into high-purity phloroglucinal
09/14/2005CN1668576A Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
09/14/2005CN1668332A Liquid formulations with a high concentration of human growth hormone (HGH) comprising glycine
09/14/2005CN1668327A Transdermal botulinum toxin compositions
09/14/2005CN1668321A Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass
09/14/2005CN1668316A Anti-spasmodic comprising xenon
09/14/2005CN1668310A Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
09/14/2005CN1668287A Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
09/14/2005CN1666748A Oral formulation of adetphos
09/13/2005US6943188 For manufacture of medicament for use in treating asthma, multiple sclerosis, inflammatory disease
09/13/2005US6943176 Heterocyclic derivatives
09/13/2005US6943163 7-Alkyl and cycloalkyl-substituted imidazotriazinones
09/13/2005US6943016 incubating a mixture of astrocytes and glial cells from patient surgical resection, culturing, astrocytes joining to the culture vessel, removing the un-attached cells; purification; treating CNS trauma, neurodegenerative disorders
09/13/2005US6943000 Detection of modulator of enzyme activity; obtain cells, incubate with modulator, monitor adjustment in enzyme activity, adjustment in activity indicates modulator
09/13/2005US6942979 Method for screening substances capable of modulating the activity of a TRAAK potassium channel
09/09/2005WO2005082905A1 Bicyclic heterocyclic compound
09/09/2005WO2005082887A1 Pyrimidine derivative
09/09/2005CA2557541A1 Pyrimidine derivatives
09/08/2005US20050197353 E.g., N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadizol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide; used for treating rheumatoid arthritis, osteoarthritis, asthma, cardiac infarction, Alzheimer's diseases, cancer diseases, atherosclerosis, etc.
09/08/2005US20050197349 Pyrrolo[2,3-D]pyrimidine compounds
09/08/2005US20050197343 N-[(4-phenyl-1-piperazinyl)alkyl]-substituted heteroarene carboxamide or 2-ferrocenyl compounds; psychiatric diseases: schizophrenia , unipolar depression, disturbances of consciousness, antidepressant; neurodegenerative diseases: Parkinson's disease, attention deficit hyperactivity syndrome; drug abuse
09/08/2005US20050197288 Administering GH-releasing factor (GRF) and analogs (hexenoyl trans-3)hGRF(1-44)NH2 for altering a lipid parameter
09/08/2005US20050197284 Providing acute neuroprotection by contacting neuronal cells with erythropoietin or active fragment or analog thereof close to or subsequent to time of excitatory insult and contacting cells with insulin-like growth factor, thereby producing synergistic acute neuroprotective effect; Alzheimer's disease
09/08/2005US20050196802 peptide of given amino acid sequence related to the sulfotransferase drug-metabolizing enzyme subfamily; use drug screening
09/07/2005EP1569668A1 An organic extract of geum japonicum thumb variant and use thereof
09/07/2005EP1569640A2 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
09/07/2005EP1569635A1 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
09/07/2005EP1405637B1 Remedies for amyotrophic lateral sclerosis (als)
09/07/2005EP1370279B1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
09/07/2005EP1366039B1 Piperazinylcarbonylquinolines and -isoquinolines
09/07/2005CN1665922A Medium for culturing autologous human progenitor stem cells and applications thereof
09/07/2005CN1665831A Novel compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules
09/07/2005CN1665829A Nonsteroidal anti-inflammatory substances, compositions and methods for their use
09/07/2005CN1665810A Inhibitors of JAK and CDK2 protein kinases
09/07/2005CN1665800A Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
09/07/2005CN1665541A Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
09/07/2005CN1665540A Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
09/07/2005CN1665533A Use of heat shock proteins to enhance efficacy of antibody therapeutics
09/07/2005CN1665503A Utilization of heteroarene carboxamide as dopamine-D3 ligands for the treatment of cns diseases
09/07/2005CN1217918C Aminocyclohexyl ether compounds and uses thereof
09/01/2005WO2005079828A2 Treatment of abnormalities of the first metatarsophalangeal joint of the foot
09/01/2005WO2004048512A3 Novel proteins and nucleic acids encoding same
09/01/2005WO2002083873A3 Enzymes
09/01/2005US20050192307 Benzimidazolone compounds
09/01/2005US20050192306 Pyrimidine derivatives as selective inhibitors of COX-2
09/01/2005US20050192260 Pharmaceutical composition
09/01/2005US20050192208 Cardiovascular disorders; antiarrhythmia agents; sodium channel moderators ; potassium channel moderators; prevent fibrillation
09/01/2005US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
09/01/2005US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells
1 ... 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 ... 233